We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+18.45%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$364M
AUM Growth
+$120M
(+49%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
28.62%
Top 10 Holdings %
Top 10 Hldgs %
53.87%
Holding
72
New
21
Increased
11
Reduced
9
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.9M |
| 2 |
Biogen
BIIB
|
+$19.2M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$19M |
| 4 |
GSK
GSK
|
+$15.5M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$12.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$13.5M |
| 2 |
Evolent Health
EVH
|
+$9.98M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$9.77M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$8.88M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$7.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.38% |
| 2 | Consumer Staples | 2.67% |
| 3 | Financials | 0.17% |
| 4 | Industrials | 0% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceuticals
TEVA
$40.7B
| $5.52M | 1.51% |
+683,613
| New | +$6.04M |
|
27
Xenon Pharmaceuticals
XENE
$6.19B
| $4.85M | 1.33% |
134,331
-32,068
| -19% | -$1.15M |
|
|
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
| $4.36M | 1.2% |
+125,000
| New | +$2.77M |
|
29
X4 Pharmaceuticals
XFOR
$389M
| $4.28M | 1.18% |
83,467
+25,524
| +44% | +$882K |
|
30
Inspire Medical Systems
INSP
$1.74B
| $4.15M | 1.14% |
23,412
-8,293
| -26% | -$1.67M |
|
|
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.42M | 0.94% |
+190,597
| New | +$2.5M |
|
32
Beam Therapeutics
BEAM
$2.78B
| $2.56M | 0.7% |
+53,754
| New | +$3.07M |
|
33
CRISPR Therapeutics
CRSP
$5.16B
| $2.38M | 0.65% |
+36,460
| New | +$2.64M |
|
|
BLU
34
DELISTED
BELLUS Health Inc.
BLU
| $2.27M | 0.62% |
214,661
-919,747
| -81% | -$9.77M |
|
35
Altimmune
ALT
$587M
| $2.01M | 0.55% |
157,303
-417,343
| -73% | -$6.16M |
|
36
Vaxcyte
PCVX
$7.97B
| $1.91M | 0.52% |
+79,411
| New | +$2.01M |
|
37
CALL
Protagonist Therapeutics
PTGX
$8.75B
| $1.68M | 0.46% |
199,500
+44,500
| +29% | +$421K |
|
|
KYNB
38
Kyntra Bio
KYNB
$28.3M
| $967K | 0.27% |
+2,974
| New | +$958K |
|
|
ACLX
39
DELISTED
Arcellx
ACLX
| $804K | 0.22% |
+42,826
| New | +$819K |
|
|
CYPH
40
Cypherpunk Technologies Inc
CYPH
$76M
| $626K | 0.17% |
+71,180
| New | +$865K |
|
41
Femasys
FEMY
$9.15M
| $120K | 0.03% |
5,330
+1,138
| +27% | +$42.8K |
|
42
Adicet Bio
ACET
$85.2M
| – | – |
-11,491
| Closed | -$2.68M |
|
43
Advantage Solutions
ADV
$424M
| – | – |
-486
| Closed | -$46K |
|
44
Aligos Therapeutics
ALGS
$29.3M
| – | – |
-1,172
| Closed | -$35K |
|
|
ALLK
45
DELISTED
Allakos
ALLK
| – | – |
-20,029
| Closed | -$63K |
|
46
Amylyx Pharmaceuticals
AMLX
$2.43B
| – | – |
-80,459
| Closed | -$1.55M |
|
47
Aveanna Healthcare
AVAH
$2.02B
| – | – |
-15,151
| Closed | -$34K |
|
48
AvePoint
AVPT
$2.85B
| – | – |
-12,140
| Closed | -$53K |
|
49
BioNTech
BNTX
$23.2B
| – | – |
-39,663
| Closed | -$5.91M |
|
50
CEL-SCI Corp
CVM
$25.7M
| – | – |
-374
| Closed | -$50K |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Tri Locum Partners held 72 positions worth $364M, up 49% from $244M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $104M of net new capital in Q3 2022, opening 21 new positions and adding to 11 existing holdings. Its largest new stake was Neurocrine Biosciences: 196,390 shares worth $20.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was BELLUS Health Inc., an estimated $9.77M trimmed.
- Tri Locum Partners's largest Q3 2022 buy was Neurocrine Biosciences: 196,390 shares worth $20.9M.
- Tri Locum Partners added most to CATALENT, INC. in Q3 2022, an estimated $12.6M increase.
- Tri Locum Partners's biggest Q3 2022 reduction was BELLUS Health Inc., cutting an estimated $9.77M.
- Tri Locum Partners fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $13.5M.
- Tri Locum Partners's ten largest holdings make up 54% of its $364M portfolio in Q3 2022.
- Tri Locum Partners opened 21 new positions and closed 31 in Q3 2022.
- Tri Locum Partners's portfolio value rose 49% quarter-over-quarter to $364M.
Based on Tri Locum Partners's 13F filing for Q3 2022, filed 14 Nov 2022.